Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 14, 2025
Finance
Insilico, Lila draw nine-figure venture rounds: Finance Report
Plus: public companies Beam, Tarsus and Mineralys raise follow-ons
BioCentury | Mar 12, 2025
Product Development
Oral peptide win for Protagonist/J&J, Beam’s base editor POC, and more: Clinical Report
Protagonist data led to week’s biggest share price gain, while Arvinas saw biggest loss: in BioCentury’s latest Clinical Report
BioCentury | May 30, 2024
Finance
Venture Report: Canadian VC Amplitude closes new fund; CinRx’s series C
Plus: Adcendo’s series A is again Denmark’s largest; VCs and foundations back Lucy
BioCentury | Sep 18, 2023
Product Development
Data comp: four hypertension candidates advancing in the clinic
Idorsia’s aprocitentan under review, while Mineralys and AZ prepare for Phase III trials and Alnylam runs two more Phase II studies
BioCentury | Sep 7, 2023
Deals
Idorsia’s hypertension lifeline
Swiss biotech Idorsia hopes near-term commercial opportunity for aprocitentan will spur investors to refinance the company
BioCentury | Jun 29, 2023
Product Development
June 29 Quick Takes: Disclosure of impropriety jeopardizes integrity of BioXcel’s trial
Plus: Laekna completes $101M Hong Kong IPO, FDA again rebuffs Alvotech’s Humira biosimilar and updates from Vesalius, Alkermes and Vertex Ventures
BioCentury | May 5, 2023
Finance
Why Acelyrin was able to generate outsized demand for its $540M IPO
Late-stage lead program draws investors’ interest, as does veteran drug-hunting leadership
BioCentury | Feb 10, 2023
Finance
In wake of CinCor takeout, market receives Mineralys’ IPO warmly
Weeks after AZ buys competitor, newly listed biotech exceeds expectations as it preps pivotal studies of ALDOS inhibitor for hypertension
BioCentury | Feb 3, 2023
Finance
Strong demand in spotlight for Structure IPO
Upsized deal gives GPCR play fourth-largest NASDAQ debut in a year
BioCentury | Jan 23, 2023
Deals
CinCor, Albireo each received higher bids in 2022 before this month’s M&A deals
Biotechs had sweeter offers, then accepted smaller proposals after share prices fell
Items per page:
1 - 10 of 25